Sökning: WFRF:(van der Ent C)
> (2020) >
Resolute zotarolimu...
Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial
-
Postma, W. (författare)
-
Fabris, E. (författare)
-
Van der Ent, M. (författare)
-
visa fler...
-
Hermanides, R. (författare)
-
Buszman, P. (författare)
-
Von Birgelen, C. (författare)
-
Cook, S. (författare)
-
- Wedel, Hans (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine
-
De Luca, G. (författare)
-
Delewi, R. (författare)
-
Zijlstra, F. (författare)
-
Kedhi, E. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2019-07-03
- 2020
- Engelska.
-
Ingår i: Catheterization and Cardiovascular Interventions. - : Wiley. - 1522-1946 .- 1522-726X. ; 95:4, s. 706-710
- Relaterad länk:
-
http://doc.rero.ch/r...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute (TM) zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627). Background R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST). Results From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%. Conclusions The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- acute myocardial infarction
- antiplatelet therapy
- coronary artery disease
- drug-eluting stent
- stent
- optical coherence tomography
- implantation
- insights
- outcomes
- Cardiovascular System & Cardiology
- esebro jh
- 1987
- circulation
- v76
- p142
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Postma, W.
-
Fabris, E.
-
Van der Ent, M.
-
Hermanides, R.
-
Buszman, P.
-
Von Birgelen, C.
-
visa fler...
-
Cook, S.
-
Wedel, Hans
-
De Luca, G.
-
Delewi, R.
-
Zijlstra, F.
-
Kedhi, E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Catheterization ...
- Av lärosätet
-
Göteborgs universitet